Skip to content
Terminus Peptides
Sign inContact
  • Research use only — not for human or veterinary use
  • 67 compound profiles, every source cited
  • 26 research materials listed
  • Prices published, not hidden behind an enquiry
  • Vials and pre-filled pens
  • Dispatched and supported from the UK
  • Every profile states its UK regulatory status
  • 5% off paying by cryptocurrency
  • Free UK delivery over £75

Policy

Scientific and medical disclaimer

The boundary between scientific discussion and medical advice, stated explicitly.

Last updated 26 August 2026.

This page is maintained by the site owner and will be professionally reviewed as the business grows; it is written to be accurate now, not aspirational.

Terminus Peptides publishes summaries of scientific literature and explanations of laboratory and regulatory concepts. This is a different activity from advising a person about their health, and the difference is not a formality.

What this site does not do

  • It does not recommend, endorse or discourage the use of any substance by any person.
  • It does not provide dosing, reconstitution, preparation, administration or sourcing information.
  • It does not diagnose, treat or offer an opinion on any individual’s circumstances.
  • It does not state that any compound is safe or effective. Where evidence is preliminary, the site says so.
  • The educational content makes no offer of sale. Research materials are listed in a separate catalogue which publishes prices but carries no ordering mechanism, and which makes no scientific claim about anything it lists.

Research context

Much of the literature discussed here concerns compounds that hold no authorisation for human use. Describing what has been studied is not a suggestion that anyone should use anything, and a compound appearing on this site should not be assumed to be lawful, available or appropriate for any purpose.

If you are unwell

Readers experiencing symptoms or concerned about a possible adverse reaction should seek advice from a healthcare professional. Suspected adverse reactions in the UK can be reported through the MHRA Yellow Card scheme, which is linked from the safety and regulation section.